Evidence map›Paper›PMID 37063883›Full record

ArticleFrontiers in immunology2023

Challenges and opportunities in analyzing and modeling peptide presentation by HLA-II proteins.

Hesham ElAbd, Petra Bacher, Andreas Tholey, Tobias L Lenz, Andre Franke

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hesham ElAbdInstitute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
Petra BacherInstitute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
Andreas TholeyProteomics & Bioanalytics, Institute for Experimental Medicine, University of Kiel, Kiel, Germany.
Tobias L LenzResearch Unit for Evolutionary Immunogenomics, Department of Biology, University of Hamburg, Hamburg, Germany.
Andre FrankeInstitute of Clinical Molecular Biology, University of Kiel, Kiel, Germany.
Christian-Albrechts-Universität zu Kiel · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human leukocyte antigen (HLA) proteins are an indispensable component of adaptive immunity because of their role in presenting self and foreign peptides to T cells. Further, many complex diseases are associated with genetic variation in the HLA region, implying an important role for specific HLA-presented peptides in the etiology of these diseases. Identifying the specific set of peptides presented by an individual's HLA proteins

Indexed as

Histocompatibility Antigens Class IHLA AntigensHistocompatibility Antigens Class IIHumansPeptidesT-LymphocytesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHLA AntigensPeptidesHLA-II & autoimmunityimmunogenicitiyimmunotherapymass-spectrometry (MS) based immunopeptidomicsneoantigenTCR - T cell receptor

Identifiers

PMID37063883
PMCPMC10090296
OpenAlexW4361288821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.